Advertisement
Singapore markets closed
  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     
  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     
  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     
  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     
  • Bitcoin USD

    56,473.59
    +2,156.80 (+3.97%)
     
  • CMC Crypto 200

    1,175.62
    -33.07 (-2.74%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • Dow

    39,375.87
    +67.87 (+0.17%)
     
  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     
  • Gold

    2,399.80
    +30.40 (+1.28%)
     
  • Crude Oil

    83.44
    -0.44 (-0.52%)
     
  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     
  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     
  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     
  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

One Humana Insider Raised Stake By 34% In Previous Year

Insiders were net buyers of Humana Inc.'s (NYSE:HUM ) stock during the past year. That is, insiders bought more stock than they sold.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Humana

The Last 12 Months Of Insider Transactions At Humana

In the last twelve months, the biggest single purchase by an insider was when Independent Director Jorge Mesquita bought US$200k worth of shares at a price of US$367 per share. That means that an insider was happy to buy shares at around the current price of US$375. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Humana share holders is that an insider was buying at near the current price. Jorge Mesquita was the only individual insider to buy shares in the last twelve months.

ADVERTISEMENT

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Humana is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership Of Humana

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 0.2% of Humana shares, worth about US$90m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Humana Tell Us?

The fact that there have been no Humana insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Humana and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Humana. Every company has risks, and we've spotted 1 warning sign for Humana you should know about.

Of course Humana may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com